11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Nexterone

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Amiodaron

Amiodaron

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Korth-Bradley JM, Rose GM, de Vane PJ, Peters J, Chiang ST. Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. J Clin Pharmacol. 1996;36:715-9.

  2. NEXTERONE (amiodarone hydrochloride injection, solution). DailyMed [www]. US National Library of Medicine. [updated 2016-11-22, cited 2019-02-27].

  3. Araki R, Yukawa E, Nakashima MN, Fukuchi H, Sasaki H, Yano K et al. Population pharmacokinetic investigation for optimization of amiodarone therapy in Japanese patients. Ther Drug Monit. 2011;33:750-6.

  4. Essebag V, Reynolds MR, Hadjis T, Lemery R, Olshansky B, Buxton AE et al. Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation. Arch Intern Med. 2007;167:1648-53.

  5. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:39D-44D.

  6. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-7.

  7. Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I, Furokawa T et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace. 2018;20(10):1565-1565ao.

  8. Antonelli D, Atar S, Freedberg NA, Rosenfeld T. Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions. Isr Med Assoc J. 2005;7:163-5.

  9. Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther. 2003;10:452-7.

  10. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects A review with special reference to torsade de pointes tachycardia. Ann Intern Med. 1994;121:529-35.

  11. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. Osteoporos Int. 2007;18:409-17.

  12. Roten L, Rimoldi SF, Schwick N, Sakata T, Heimgartner C, Fuhrer J et al. Gender differences in patients referred for atrial fibrillation management to a tertiary center. Pacing Clin Electrophysiol. 2009;32:622-6.

  13. Bouvy ML, Heerdink ER, Hoes AW, Leufkens HG. Amiodarone-induced thyroid dysfunction associated with cumulative dose. Pharmacoepidemiol Drug Saf. 2002;11(7):601-6.

  14. Jackevicius CA, Tom A, Essebag V, Eisenberg MJ, Rahme E, Tu JV et al. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol. 2011;108:705-10.

  15. Cheng HC, Yeh HJ, Huang N, Chou YJ, Yen MY, Wang AG. Amiodarone-Associated Optic Neuropathy: A Nationwide Study. Ophthalmology. 2015;122(12):2553-9.

  16. Su VY, Hu YW, Chou KT, Ou SM, Lee YC, Lin EY et al. Amiodarone and the risk of cancer: a nationwide population-based study. Cancer. 2013;119(9):1699-705.

  17. Lai SW, Lin CL, Liao KF, Lin CY. Amiodarone use and risk of acute pancreatitis: A population-based case-control study. Heart Rhythm. 2015;12(1):163-6.

  18. Carnlöf C, Iwarzon M, Jensen-Urstad M, Gadler F, Insulander P. Women with PSVT are often misdiagnosed, referred later than men, and have more symptoms after ablation. Scand Cardiovasc J. 2017;51(6):299-307.

  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]

  1. Korth-Bradley JM, Rose GM, de Vane PJ, Peters J, Chiang ST. Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. J Clin Pharmacol. 1996;36:715-9.
  2. NEXTERONE (amiodarone hydrochloride injection, solution). DailyMed [www]. US National Library of Medicine. [updated 2016-11-22, cited 2019-02-27].
  3. Araki R, Yukawa E, Nakashima MN, Fukuchi H, Sasaki H, Yano K et al. Population pharmacokinetic investigation for optimization of amiodarone therapy in Japanese patients. Ther Drug Monit. 2011;33:750-6.
  4. Essebag V, Reynolds MR, Hadjis T, Lemery R, Olshansky B, Buxton AE et al. Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation. Arch Intern Med. 2007;167:1648-53.
  5. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:39D-44D.
  6. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-7.
  7. Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I, Furokawa T et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace. 2018;20(10):1565-1565ao.
  8. Antonelli D, Atar S, Freedberg NA, Rosenfeld T. Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions. Isr Med Assoc J. 2005;7:163-5.
  9. Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther. 2003;10:452-7.
  10. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects A review with special reference to torsade de pointes tachycardia. Ann Intern Med. 1994;121:529-35.
  11. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. Osteoporos Int. 2007;18:409-17.
  12. Roten L, Rimoldi SF, Schwick N, Sakata T, Heimgartner C, Fuhrer J et al. Gender differences in patients referred for atrial fibrillation management to a tertiary center. Pacing Clin Electrophysiol. 2009;32:622-6.
  13. Bouvy ML, Heerdink ER, Hoes AW, Leufkens HG. Amiodarone-induced thyroid dysfunction associated with cumulative dose. Pharmacoepidemiol Drug Saf. 2002;11(7):601-6.
  14. Jackevicius CA, Tom A, Essebag V, Eisenberg MJ, Rahme E, Tu JV et al. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol. 2011;108:705-10.
  15. Cheng HC, Yeh HJ, Huang N, Chou YJ, Yen MY, Wang AG. Amiodarone-Associated Optic Neuropathy: A Nationwide Study. Ophthalmology. 2015;122(12):2553-9.
  16. Su VY, Hu YW, Chou KT, Ou SM, Lee YC, Lin EY et al. Amiodarone and the risk of cancer: a nationwide population-based study. Cancer. 2013;119(9):1699-705.
  17. Lai SW, Lin CL, Liao KF, Lin CY. Amiodarone use and risk of acute pancreatitis: A population-based case-control study. Heart Rhythm. 2015;12(1):163-6.
  18. Carnlöf C, Iwarzon M, Jensen-Urstad M, Gadler F, Insulander P. Women with PSVT are often misdiagnosed, referred later than men, and have more symptoms after ablation. Scand Cardiovasc J. 2017;51(6):299-307.
  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]